Literature DB >> 26262010

Nonadherence to Oral Antihyperglycemic Agents: Subsequent Hospitalization and Mortality among Patients with Type 2 Diabetes in Clinical Practice.

Vivienne J Zhu1, Wanzhu Tu2, Marc B Rosenman1, J Marc Overhage3.   

Abstract

Using real-world clinical data from the Indiana Network for Patient Care, we analyzed the associations between non-adherence to oral antihyperglycemic agents (OHA) and subsequent diabetes-related hospitalization and all-cause mortality for patients with type 2 diabetes. OHA adherence was measured by the annual proportion of days covered (PDC) for 2008 and 2009. Among 24,067 eligible patients, 35,507 annual PDCs were formed. Over 90% (n=21,798) of the patients had a PDC less than 80%. In generalized linear mixed model analyses, OHA non-adherence is significantly associated with diabetes related hospitalizations (OR: 1.2; 95% CI [1.1,1.3]; p<0.0001). Older patients, white patients, or patients who had ischemic heart disease, stroke, or renal disease had higher odds of hospitalization. Similarly, OHA non-adherence increased subsequent mortality (OR: 1.3; 95% CI [1.02, 1.61]; p<0.0001). Patient age, male gender, income and presence of ischemic heart diseases, stroke, and renal disease were also significantly associated with subsequent all-cause death.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26262010

Source DB:  PubMed          Journal:  Stud Health Technol Inform        ISSN: 0926-9630


  7 in total

1.  Racial and Regional Disparities in Outcomes Among Veterans Initially Adherent to Oral Antidiabetic Therapies: an Observational Cohort Study.

Authors:  Justin Gatwood; Marie Chisholm-Burns; Robert Davis; Fridtjof Thomas; Praveen Potukuchi; Adriana Hung; Csaba P Kovesdy
Journal:  J Gen Intern Med       Date:  2020-01-08       Impact factor: 5.128

2.  Kidney Histopathology and Prediction of Kidney Failure: A Retrospective Cohort Study.

Authors:  Michael T Eadon; Tae-Hwi Schwantes-An; Carrie L Phillips; Anna R Roberts; Colin V Greene; Ayman Hallab; Kyle J Hart; Sarah N Lipp; Claudio Perez-Ledezma; Khawaja O Omar; Katherine J Kelly; Sharon M Moe; Pierre C Dagher; Tarek M El-Achkar; Ranjani N Moorthi
Journal:  Am J Kidney Dis       Date:  2020-04-24       Impact factor: 8.860

Review 3.  Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.

Authors:  Marc Evans; Susanne Engberg; Mads Faurby; João Diogo Da Rocha Fernandes; Pollyanna Hudson; William Polonsky
Journal:  Diabetes Obes Metab       Date:  2021-12-09       Impact factor: 6.408

4.  Diabetes hospitalizations and deaths in a cohort of treatment-seeking illicit drug users.

Authors:  Alex Aregbesola; Ifeoma N Onyeka; Olubunmi Olubamwo; Kimmo Ronkainen; Jari Tiihonen; Jaana Föhr; Jussi Kauhanen
Journal:  SAGE Open Med       Date:  2018-05-01

5.  A personalised intervention programme aimed at improving adherence to oral antidiabetic and/or antihypertensive medication in people with type 2 diabetes mellitus, the INTENSE study: study protocol for a randomised controlled trial.

Authors:  Marlous Langendoen-Gort; Hiyam Al-Jabr; Jacqueline G Hugtenburg; Femke Rutters; Maartje de Wit; Debi Bhattacharya; Ameen Abu-Hanna; Andrew Farmer; Petra J M Elders
Journal:  Trials       Date:  2022-09-02       Impact factor: 2.728

Review 6.  Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin.

Authors:  Stanley S Schwartz; Arie Katz
Journal:  Diabetes Metab Syndr Obes       Date:  2016-03-15       Impact factor: 3.168

7.  Feasibility study of a digitalized nurse practitioner-led intervention to improve medication adherence in type 2 diabetes patients in Dutch primary care.

Authors:  Stijn Hogervorst; Marcel Adriaanse; Hella Brandt; Marcia Vervloet; Liset van Dijk; Jacqueline Hugtenburg
Journal:  Pilot Feasibility Stud       Date:  2021-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.